A detailed history of Blue Chip Partners, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Blue Chip Partners, Inc. holds 181,338 shares of ABBV stock, worth $29.9 Million. This represents 3.11% of its overall portfolio holdings.

Number of Shares
181,338
Previous 182,528 0.65%
Holding current value
$29.9 Million
Previous $31.3 Million 14.38%
% of portfolio
3.11%
Previous 2.89%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$163.84 - $199.33 $194,969 - $237,202
-1,190 Reduced 0.65%
181,338 $35.8 Million
Q2 2024

Jul 29, 2024

BUY
$154.79 - $180.76 $821,625 - $959,474
5,308 Added 3.0%
182,528 $31.3 Million
Q1 2024

Apr 25, 2024

SELL
$159.82 - $182.1 $354,640 - $404,079
-2,219 Reduced 1.24%
177,220 $32.3 Million
Q4 2023

Feb 05, 2024

BUY
$137.6 - $154.97 $326,662 - $367,898
2,374 Added 1.34%
179,439 $27.8 Million
Q3 2023

Oct 30, 2023

BUY
$133.59 - $154.65 $579,379 - $670,717
4,337 Added 2.51%
177,065 $26.4 Million
Q2 2023

Aug 02, 2023

SELL
$132.51 - $164.9 $130,787 - $162,756
-987 Reduced 0.57%
172,728 $23.3 Million
Q1 2023

May 01, 2023

SELL
$144.61 - $166.54 $385,530 - $443,995
-2,666 Reduced 1.51%
173,715 $27.7 Million
Q4 2022

Feb 01, 2023

SELL
$138.31 - $165.87 $2.03 Million - $2.43 Million
-14,667 Reduced 7.68%
176,381 $28.5 Million
Q3 2022

Oct 27, 2022

BUY
$134.21 - $153.93 $695,476 - $797,665
5,182 Added 2.79%
191,048 $25.6 Million
Q2 2022

Aug 01, 2022

BUY
$137.62 - $174.96 $339,921 - $432,151
2,470 Added 1.35%
185,866 $28.5 Million
Q1 2022

May 04, 2022

BUY
$131.98 - $163.75 $114,030 - $141,480
864 Added 0.47%
183,396 $29.7 Million
Q4 2021

Feb 08, 2022

BUY
$107.43 - $135.93 $565,833 - $715,943
5,267 Added 2.97%
182,532 $24.7 Million
Q3 2021

Nov 02, 2021

BUY
$106.4 - $120.78 $373,144 - $423,575
3,507 Added 2.02%
177,265 $19.1 Million
Q2 2021

Aug 03, 2021

BUY
$105.21 - $117.21 $445,143 - $495,915
4,231 Added 2.5%
173,758 $19.6 Million
Q1 2021

May 04, 2021

SELL
$102.3 - $112.62 $615,436 - $677,521
-6,016 Reduced 3.43%
169,527 $18.3 Million
Q4 2020

Feb 05, 2021

BUY
$80.49 - $108.67 $633,697 - $855,558
7,873 Added 4.7%
175,543 $18.8 Million
Q3 2020

Oct 27, 2020

BUY
$85.91 - $100.83 $327,059 - $383,859
3,807 Added 2.32%
167,670 $14.7 Million
Q2 2020

Jul 30, 2020

BUY
$73.37 - $98.18 $550,054 - $736,055
7,497 Added 4.79%
163,863 $16.1 Million
Q1 2020

May 08, 2020

SELL
$64.5 - $97.79 $292,120 - $442,890
-4,529 Reduced 2.81%
156,366 $11.9 Million
Q4 2019

Feb 11, 2020

BUY
$72.13 - $90.25 $938,267 - $1.17 Million
13,008 Added 8.8%
160,895 $14.2 Million
Q3 2019

Oct 29, 2019

BUY
$62.98 - $75.72 $901,558 - $1.08 Million
14,315 Added 10.72%
147,887 $11.2 Million
Q2 2019

Jul 31, 2019

BUY
$65.7 - $83.98 $661,664 - $845,762
10,071 Added 8.15%
133,572 $9.71 Million
Q1 2019

Apr 23, 2019

BUY
$77.14 - $90.79 $943,190 - $1.11 Million
12,227 Added 10.99%
123,501 $9.95 Million
Q4 2018

Feb 05, 2019

SELL
$77.85 - $96.01 $33,086 - $40,804
-425 Reduced 0.38%
111,274 $10.3 Million
Q3 2018

Oct 26, 2018

BUY
$88.91 - $98.84 $447,928 - $497,955
5,038 Added 4.72%
111,699 $10.6 Million
Q2 2018

Jul 25, 2018

BUY
$89.78 - $106.23 $484,452 - $573,217
5,396 Added 5.33%
106,661 $9.88 Million
Q1 2018

Apr 25, 2018

BUY
$92.01 - $123.21 $489,677 - $655,723
5,322 Added 5.55%
101,265 $9.59 Million
Q4 2017

Jan 31, 2018

BUY
$89.56 - $98.21 $99,142 - $108,718
1,107 Added 1.17%
95,943 $9.28 Million
Q3 2017

Nov 07, 2017

BUY
$69.85 - $89.22 $272,624 - $348,225
3,903 Added 4.29%
94,836 $8.43 Million
Q2 2017

Aug 07, 2017

BUY
N/A
90,933
90,933 $6.59 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $292B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Blue Chip Partners, Inc. Portfolio

Follow Blue Chip Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blue Chip Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Blue Chip Partners, Inc. with notifications on news.